International trends in clozapine use: a study in 17 countries

Acta Psychiatrica Scandinavica

Volumn 136, Issue 1, 2017, Pages 37-51

  Bachmann, C J ^a   Aagaard, L ^b   Bernardo, M ^c   Brandt, L ^d   Cartabia, M ^e   Clavenna, A ^e   Coma Fuste A ^f   Furu, K ^g   Garuoliene K ^h,i   Hoffmann, F ^j   Hollingworth, S ^k   Huybrechts, K F ^l   Kalverdijk, L J ^m   Kawakami, K ⁿ   Kieler, H ^d   Kinoshita, T ⁿ   Lopez S C ^o   Machado Alba, J E ^o   Machado Duque, M E ^o   Mahesri, M ^l   Nishtala, P S ^p   Piovani, D ^e   Reutfors, J ^d   Saastamoinen, L K ^q   Sato, I ⁿ   Schuiling Veninga, C C M ^r   Shyu, Y C ^s,t,u   Siskind, D ^k   Skurtveit, S ^g   Verdoux, H ^v   Wang, L J ^w   Zara Yahni, C ^f   Zoega H ^v   Taylor, D ^x,y   more..

^a Freelance Researcher   (Germany)

^b Team Work Life   (Denmark)

^c UNIVERSITY OF BARCELONA   (Spain)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f C Agy Hlth Technol Assess Res   (Spain)

^g NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^h Medicines Reimbursement Department   (Lithuania)

ⁱ VILNIUS UNIVERSITY   (Lithuania)

^j UNIVERSITY OF OLDENBURG   (Germany)

^k UNIVERSITY OF QUEENSLAND   (Australia)

^l BRIGHAM AND WOMEN S HOSPITAL   (United States)

^m UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

ⁿ KYOTO UNIVERSITY   (Japan)

^o UNIVERSIDAD TECNOLÓGICA DE PEREIRA   (Colombia)

^p UNIVERSITY OF OTAGO   (New Zealand)

^q SOCIAL INSURANCE INSTITUTION   (Finland)

^r UNIVERSITY OF GRONINGEN   (Netherlands)

^s CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^t INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^u CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^v UNIVERSITÉ DE BORDEAUX   (France)

^w CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^x SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^y KING'S COLLEGE LONDON   (United Kingdom)

more..

Author keywords

clozapine; pharmacoepidemiology; psychotic disorders

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CHILD; COLOMBIA; CROSS-SECTIONAL STUDY; DENMARK; DRUG USE; FEMALE; FINLAND; FRANCE; GERMANY; HUMAN; ICELAND; ITALY; JAPAN; LITHUANIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NETHERLANDS; NEW ZEALAND; NORWAY; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SCHOOL CHILD; SEX DIFFERENCE; SPAIN; SUICIDAL BEHAVIOR; SWEDEN; TAIWAN; TREATMENT-RESISTANT SCHIZOPHRENIA; UNITED STATES; VERY ELDERLY; YOUNG ADULT; CLINICAL TRIAL; DRUG UTILIZATION; MULTICENTER STUDY; PRESCRIPTION; STATISTICS AND NUMERICAL DATA; TRENDS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; CROSS-SECTIONAL STUDIES; DRUG PRESCRIPTIONS; DRUG UTILIZATION; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 85018900061     PISSN: 0001690X     EISSN: 16000447     Source Type: Journal    
DOI: 10.1111/acps.12742     Document Type: Article

References (86)

1. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry 2007;18:39–60.
2. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva I. Letter: clozapine and agranulocytosis. Lancet 1975;2:611.
3. Nielsen J, Young C, Ifteni P et al. Worldwide differences in regulations of clozapine use. CNS Drugs 2016;30:149–161.
4. Schneider C, Corrigall R, Hayes D, Kyriakopoulos M, Frangou S. Systematic review of the efficacy and tolerability of clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 2014;29:1–10.
5. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 2016;209:385–392.
6. Vanasse A, Blais L, Courteau J et al. Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study. Acta Psychiatr Scand 2016;134:374–384.
7. World Health Organisation. WHO model list of essential medicines, 19th list. Geneva: WHO, 2015. Available from: http://www.who.int/medicines/publications/essentialmedicines/en/
8. Remington G, Lee J, Agid O et al. Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use. Expert Opin Drug Saf 2016;15:1193–1203.
9. Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 2015;132:231–240.
10. Stubbs B, Vancampfort D, de Hert M, Mitchell AJ. The prevalence and predictors of type two diabetes mellitus in people with schizophrenia: a systematic review and comparative meta-analysis. Acta Psychiatr Scand 2015;132:144–157.
11. Manu P, Dima L, Shulman M, Vancampfort D, de Hert M, Correll CU. Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management. Acta Psychiatr Scand 2015;132:97–108.
12. Kelly DL, Wehring HJ, Vyas G. Current status of clozapine in the United States. Shanghai Arch Psychiatry 2012;24:110–113.
13. McClellan J, Stock S. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry 2013;52:976–990.
14. Goren JL, Meterko M, Williams S et al. Antipsychotic prescribing pathways, polypharmacy, and clozapine use in treatment of schizophrenia. Psychiatr Serv 2013;64:527–533.
15. Latimer E, Wynant W, Clark R et al. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Quebec. Clin Schizophr Relat Psychoses 2013;7:33–41.
16. Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 2015;72:334–341.
17. Tiihonen J, Lonnqvist J, Wahlbeck K et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620–627.
18. Warnez S, Alessi-Severini S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry 2014;14:102.
19. Nielsen J, Roge R, Schjerning O, Sorensen HJ, Taylor D. Geographical and temporal variations in clozapine prescription for schizophrenia. Eur Neuropsychopharmacol 2012;22:818–824.
20. Cirulli G. Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units. Psychiatr Bull 2005;29:377–380.
21. Legge SE, Hamshere M, Hayes RD et al. Reasons for discontinuing clozapine: a cohort study of patients commencing treatment. Schizophr Res 2016;174:113–119.
22. Gee S, Vergunst F, Howes O, Taylor D. Practitioner attitudes to clozapine initiation. Acta Psychiatr Scand 2014;130:16–24.
23. Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 2012;201:481–485.
24. Verdoux H, Pambrun E, Cortaredona S et al. Geographical disparities in prescription practices of lithium and clozapine: a community-based study. Acta Psychiatr Scand 2016;133:470–480.
25. Grover S, Balachander S, Chakarabarti S, Avasthi A. Prescription practices and attitude of psychiatrists towards clozapine: a survey of psychiatrists from India. Asian J Psychiatr 2015;18:57–65.
26. Nielsen J, Dahm M, Lublin H, Taylor D. Psychiatrists’ attitude towards and knowledge of clozapine treatment. J Psychopharmacol 2010;24:965–971.
27. Forrester T, Siskind D, Winckel K, Wheeler A, Hollingworth S. Increasing clozapine dispensing trends in Queensland, Australia 2004–2013. Pharmacopsychiatry 2015;48:164–169.
28. Pringsheim T, Lam D, Tano DS, Patten SB. The pharmacoepidemiology of antipsychotics for adults with schizophrenia in Canada, 2005 to 2009. Can J Psychiatry 2011;56:630–634.
29. Moore TA, Covell NH, Essock SM, Miller AL. Real-world antipsychotic treatment practices. Psychiatr Clin North Am 2007;30:401–416.
30. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs, 2016. Oslo, Norway, 2015.
31. Ahmad OB, Boschi-Pinto C, Lopez AD, Murray CJ, Lozano R, Inoue M. Age standardization of rates: A new WHO Standard. GPE Discussion Paper Series: No. 31. Geneva: World Health Organisation, 2001.
32. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev 2008;30:67–76.
33. Simeone JC, Ward AJ, Rotella P, Collins J, Windisch R. An evaluation of variation in published estimates of schizophrenia prevalence from 1990─2013: a systematic literature review. BMC Psychiatry 2015;15:193.
34. Agid O, Arenovich T, Sajeev G et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry 2011;72:1439–1444.
35. Juarez-Reyes MG, Shumway M, Battle C, Bacchetti P, Hansen MS, Hargreaves WA. Effects of stringent criteria on eligibility for clozapine among public mental health clients. Psychiatr Serv 1995;46:801–806.
36. Stroup TS, Gerhard T, Crystal S, Huang C, Olfson M. Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv 2014;65:186–192.
37. Bachmann C, Aagaard L, Burcu M et al. Trends and patterns of antidepressant use in children and adolescents from five western countries, 2005–2012. Eur Neuropsychopharmacol 2016;26:411–419.
38. Schomerus G, Matschinger H, Baumeister SE, Mojtabai R, Angermeyer MC. Public attitudes towards psychiatric medication: a comparison between United States and Germany. World Psychiatry 2014;13:320–321.
39. Rissmiller DJ, Rissmiller JH. Evolution of the antipsychiatry movement into mental health consumerism. Psychiatr Serv 2006;57:863–866.
40. Romanucci-Ross L. The deinstitutionalization movement in Italy. Ideological thrust to cultural error. Int J Technol Assess Health Care 1996;12:634–643.
41. Bleandonu G. Psychodynamic psychiatry and the treatment of psychosis in the French community. Bull Menninger Clin 1995;59:372–384.
42. Takeuchi I, Hanya M, Uno J et al. A questionnaire-based study of the views of schizophrenia patients and psychiatric healthcare professionals in Japan about the side effects of clozapine. Clin Psychopharmacol Neurosci 2016;14:286–294.
43. Xiang YT, Ungvari GS, Correll CU, Chiu HF, Shinfuku N. Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia. Epidemiol Psychiatr Sci 2016;25:9–17.
44. Yoshio T, Inada T, Uno J et al. Prescription profiles for pharmacological treatment of Japanese inpatients with schizophrenia: comparison between 2007 and 2009. Hum Psychopharmacol 2012;27:70–75.
45. Haro JM, Novick D, Bertsch J, Karagianis J, Dossenbach M, Jones PB. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry 2011;199:194–201.
46. Tiihonen J, Wahlbeck K, Lonnqvist J et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006;333:224.
47. Thomas KL, Jiang Y, McCombs JS. Clozapine revisited: impact of clozapine vs olanzapine on health care use by schizophrenia patients on Medicaid. Ann Clin Psychiatry 2015;27:90–99.
48. Tharyan P. Haematological monitoring with clozapine therapy in India. Br J Psychiatry 1998;172:540.
49. Management Sciences for Health. International drug price indicator guide. Geneva: World Health Organization, 2014 [updated 2014; cited 2016 07.11.2016]; Available from: http://erc.msh.org/priceguide
50. Kim E, Gupta S, Bolge S, Chen CC, Whitehead R, Bates JA. Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey. J Med Econ 2010;13:185–192.
51. Koskinen H, Ahola E, Saastamoinen LK, Mikkola H, Martikainen JE. The impact of reference pricing and extension of generic substitution on the daily cost of antipsychotic medication in Finland. Health Econ Rev 2014;4:9.
52. Quitian Reyes H, Arciniegas Barrera JA, Bohorquez Penaranda A, Gomez Restrepo C. [Cost-effectiveness of antipsychotics in the maintenance treatment of schizophrenia in Colombia]. Rev Colomb Psiquiatr 2016;45:67–74.
53. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999;60(Suppl. 12):22–23.
54. Kasoff LI, Ahn K, Gochman P, Broadnax DD, Rapoport JL. Strong treatment response and high maintenance rates of clozapine in childhood-onset schizophrenia. J Child Adolesc Psychopharmacol 2016;26:428–435.
55. Mustafa FA, Burke JG, Abukmeil SS, Scanlon JJ, Cox M. “Schizophrenia past clozapine”: reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing. Pharmacopsychiatry 2015;48:11–14.
56. Farooq S, Taylor M. Clozapine: dangerous orphan or neglected friend? Br J Psychiatry 2011;198:247–249.
57. Ingimarsson O, Maccabe JH, Haraldsson M, Jonsdottir H, Sigurdsson E. Clozapine treatment and discontinuation in Iceland: a national longitudinal study using electronic patient records. Nord J Psychiatry 2016;70:450–455.
58. Lally J, Gaughran F, Timms P, Curran SR. Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics. Pharmgenomics Pers Med 2016;9:117–129.
59. Castle D, Sham P, Murray R. Differences in distribution of ages of onset in males and females with schizophrenia. Schizophr Res 1998;33:179–183.
60. Trinczek E, Heinzel-Gutenbrunner M, Haberhausen M, Bachmann CJ. Time to initiation of clozapine treatment in children and adolescents with early-onset schizophrenia. Pharmacopsychiatry 2016;49:254–259.
61. Patel M, Joshi A, Suthar J, Desai S. Drug utilization pattern in patients with different types of dementia in Western India. Int J Alzheimers Dis 2014;2014:435202.
62. Verdoux H, Pambrun E. Clozapine use pattern in persons with and without treatment for Parkinson's disease in real-world conditions: a naturalistic study in a community-based sample. Acta Psychiatr Scand 2014;130:487–497.
63. American Geriatrics Society. Updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227–2246.
64. Driver DI, Gogtay N, Rapoport JL. Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am 2013;22:539–555.
65. Schneider C, Papachristou E, Wimberley T et al. Clozapine use in childhood and adolescent schizophrenia: a nationwide population-based study. Eur Neuropsychopharmacol 2015;25:857–863.
66. Ordonez AE, Loeb FF, Zhou X et al. Lack of gender-related differences in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry 2016;55:792–799.
67. Beck K, McCutcheon R, Bloomfield MA et al. The practical management of refractory schizophrenia–the Maudsley Treatment Review and Assessment Team service approach. Acta Psychiatr Scand 2014;130:427–438.
68. Carruthers J, Radigan M, Erlich MD et al. An initiative to improve clozapine prescribing in New York State. Psychiatr Serv 2016;67:369–371.
69. Clark SR, Wilton L, Baune BT, Procter N, Hustig H. A state-wide quality improvement system utilising nurse-led clinics for clozapine management. Australas Psychiatry 2014;22:254–259.
70. Bogers JP, Schulte PF, van Dijk D, Bakker B, Cohen D. Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved? J Clin Psychopharmacol 2016;36:109–111.
71. Machado-Alba JE, Morales-Plaza CD. [Antipsychotic prescription patterns in patients affiliated to the Social Security Health System in Colombia]. Biomedica 2013;33:418–428.
72. Machado-Alba JE, Morales Plaza CD, Solarte Gomez MJ. [Antidepressant prescription patterns in patients affiliated with the General Social Security Health System of Colombia]. Rev Panam Salud Publica 2011;30:461–468.
73. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merliere Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010;58:286–290.
74. Hoffmann F, Bachmann CJ. [Differences in sociodemographic characteristics, health, and health service use of children and adolescents according to their health insurance funds]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2014;57:455–463.
75. Clavenna A, Cartabia M, Sequi M et al. Burden of psychiatric disorders in the pediatric population. Eur Neuropsychopharmacol 2013;23:98–106.
76. Piovani D, Clavenna A, Cartabia M, Bonati M. Psychotropic medicine prescriptions in Italian youths: a multiregional study. Eur Child Adolesc Psychiatry 2016;25:235–245.
77. Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci 2015;1:16.
78. Takahashi Y, Nishida Y, Asai S. Utilization of health care databases for pharmacoepidemiology. Eur J Clin Pharmacol 2012;68:123–129.
79. Garuoliene K, Godman B, Gulbinovic J, Schiffers K, Wettermark B. Differences in utilization rates between commercial and administrative databases: implications for future health-economic and cross-national studies. Expert Rev Pharmacoecon Outcomes Res 2016;16:149–152.
80. Ndukwe HC, Tordoff JM, Wang T, Nishtala PS. Psychotropic medicine utilization in older people in New Zealand from 2005 to 2013. Drugs Aging 2014;31:755–768.
81. Visser ST, Schuiling-Veninga CC, Bos JH, De Jong-Van den Berg T, Postma MJ. The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges. Expert Rev Pharmacoecon Outcomes Res 2013;13:285–292.
82. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, Sorensen HT. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86–94.
83. Wu CS, Lai MS, Gau SS, Wang SC, Tsai HJ. Concordance between patient self-reports and claims data on clinical diagnoses, medication use, and health system utilization in Taiwan. PLoS One 2014;9:e112257.
84. Wang LJ, Lee SY, Yuan SS et al. Risk of mortality among patients treated with antipsychotic medications: a nationwide population-based study in Taiwan. J Clin Psychopharmacol 2016;36:9–17.
85. Centers for Medicare & Medicaid Services. Medicaid Analytic eXtract (MAX) general information. Journal [serial on the Internet]. 2017. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Computer-Data-and-Systems/MedicaidDataSourcesGenInfo/MAXGeneralInformation.html
86. Seeger J, Daniel GW. Commercial insurance databases. In: Strom BL, Kimmel SE, Hennessy S, eds. Pharmacoepidemiolog, 5th edn. Philadelphia, PA: Wiley & Sons; 2012; 189–208.